Alentis Therapeutics: Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) ALE.F02 found to be well tolerated at all doses with a good safety profile and

Related Keywords

France ,Switzerland ,Nathalie Graf Tschupp ,Kostenloser Wertpapierhandel ,Roberto Iacone ,Markus Meyer ,French National Institute Of Health Inserm ,University Of Strasbourg ,Consilium Strategic Communications International ,Alentis Therapeutics ,Thomas Baumert ,French National Institute ,Strategic Communications ,Jane Elliott Matthew Cole Ashley Tapp ,Valentis ,Herapeutics ,Positive ,Results ,Rom ,Single ,Ascending ,Nose ,Hase ,Study ,Targeting ,Claudin ,